Literature DB >> 19460870

Neural activity changes to emotional stimuli in healthy individuals under chronic use of clomipramine.

J R Cardoso de Almeida1, M L Phillips, C T Cerqueira, M Zilberman, D Lobo, E Henna, H Tavares, E Amaro, C Gorenstein, V Gentil, G F Busatto.   

Abstract

Previous functional magnetic resonance imaging (fMRI) studies examined neural activity responses to emotive stimuli in healthy individuals after acute/subacute administration of antidepressants. We now report the effects of repeated use of the antidepressant clomipramine on fMRI data acquired during presentation of emotion-provoking and neutral stimuli on healthy volunteers. A total of 12 volunteers were evaluated with fMRI after receiving low doses of clomipramine for 4 weeks and again after 4 weeks of washout. Fear-, happiness-, anger-provoking and neutral pictures from the International Affective Picture System (IAPS) were used. Data analysis was performed with statistical parametric mapping (P < 0.05). Paired t-test comparisons for each condition between medicated and unmedicated states showed, to negative valence paradigms, decrease in brain activity in the amygdala when participants were medicated. We also demonstrated, across both positive and negative valence paradigms, consistent decreases in brain activity in the medicated state in the anterior cingulate gyrus and insula. This is the first report of modulatory effects of repeated antidepressant use on the central representation of somatic states in response to emotions of both negative and positive valences in healthy individuals. Also, our results corroborate findings of antidepressant-induced temporolimbic activity changes to emotion-provoking stimuli obtained in studies of subjects treated acutely with such agents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19460870      PMCID: PMC2889163          DOI: 10.1177/0269881109105786

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  43 in total

1.  A dose-finding and discontinuation study of clomipramine in panic disorder.

Authors:  F Lotufo-Neto; M Bernik; R T Ramos; L Andrade; C Gorenstein; T Cordas; M Melo; V Gentil
Journal:  J Psychopharmacol       Date:  2001-03       Impact factor: 4.153

2.  Acute SSRI administration affects the processing of social cues in healthy volunteers.

Authors:  C J Harmer; Z Bhagwagar; D I Perrett; B A Völlm; P J Cowen; G M Goodwin
Journal:  Neuropsychopharmacology       Date:  2003-01       Impact factor: 7.853

3.  The effects of reboxetine on emotional processing in healthy volunteers: an fMRI study.

Authors:  R Norbury; C E Mackay; P J Cowen; G M Goodwin; C J Harmer
Journal:  Mol Psychiatry       Date:  2007-10-23       Impact factor: 15.992

4.  Reciprocal effects of antidepressant treatment on activity and connectivity of the mood regulating circuit: an FMRI study.

Authors:  Amit Anand; Yu Li; Yang Wang; Kathryn Gardner; Mark J Lowe
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2007       Impact factor: 2.198

5.  Clomipramine-induced mood and perceived performance changes in selected healthy individuals.

Authors:  Valentim Gentil; Monica L Zilberman; Daniela Lobo; Elaine Henna; Ricardo A Moreno; Clarice Gorenstein
Journal:  J Clin Psychopharmacol       Date:  2007-06       Impact factor: 3.153

Review 6.  Neurobiology of emotion perception I: The neural basis of normal emotion perception.

Authors:  Mary L Phillips; Wayne C Drevets; Scott L Rauch; Richard Lane
Journal:  Biol Psychiatry       Date:  2003-09-01       Impact factor: 13.382

7.  A double dissociation of ventromedial prefrontal cortical responses to sad and happy stimuli in depressed and healthy individuals.

Authors:  Paul A Keedwell; Chris Andrew; Steven C R Williams; Mick J Brammer; Mary L Phillips
Journal:  Biol Psychiatry       Date:  2005-07-05       Impact factor: 13.382

Review 8.  Pharmacological treatment for unipolar psychotic depression: Systematic review and meta-analysis.

Authors:  Jaap Wijkstra; Jeroen Lijmer; Ferdi J Balk; John R Geddes; Willem A Nolen
Journal:  Br J Psychiatry       Date:  2006-05       Impact factor: 9.319

9.  Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response.

Authors:  H S Mayberg; S K Brannan; J L Tekell; J A Silva; R K Mahurin; S McGinnis; P A Jerabek
Journal:  Biol Psychiatry       Date:  2000-10-15       Impact factor: 13.382

10.  Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.

Authors:  Catherine J Harmer; Nicholas C Shelley; Philip J Cowen; Guy M Goodwin
Journal:  Am J Psychiatry       Date:  2004-07       Impact factor: 18.112

View more
  4 in total

Review 1.  Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches.

Authors:  Mary L Phillips; Henry W Chase; Yvette I Sheline; Amit Etkin; Jorge R C Almeida; Thilo Deckersbach; Madhukar H Trivedi
Journal:  Am J Psychiatry       Date:  2015-02-01       Impact factor: 18.112

2.  Facial emotion processing in major depression: a systematic review of neuroimaging findings.

Authors:  Anja Stuhrmann; Thomas Suslow; Udo Dannlowski
Journal:  Biol Mood Anxiety Disord       Date:  2011-11-07

3.  Abnormal left-sided orbitomedial prefrontal cortical-amygdala connectivity during happy and fear face processing: a potential neural mechanism of female MDD.

Authors:  Jorge Renner Cardoso de Almeida; Dina Michaela Kronhaus; Etienne L Sibille; Scott A Langenecker; Amelia Versace; Edmund James Labarbara; Mary Louise Phillips
Journal:  Front Psychiatry       Date:  2011-12-08       Impact factor: 4.157

4.  Healthy individuals treated with clomipramine: an fMRI study of brain activity during autobiographical recall of emotions.

Authors:  C T Cerqueira; J R Sato; J R C de Almeida; E Amaro; C C Leite; C Gorenstein; V Gentil; G F Busatto
Journal:  Transl Psychiatry       Date:  2014-07-01       Impact factor: 6.222

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.